Socioeconomic Factors Impact ASCT Completion, Clinical Outcomes in MCL: Yazeed Sawalha, MD

Video

The hematologist from Ohio State University Comprehensive Cancer Center–The James discussed the impact of socioeconomic factors on completion of autologous stem cell transplant in patients with mantle cell lymphoma.

This content originally appeared on our sister site, CancerNetwork.

Factors such as insurance type, treatment facility, and location are associated with chances of completing autologous stem cell transplant (ASCT), and education and race impact survival outcomes.

CancerNetwork® spoke with Yazeed Sawalha, MD, a hematologist at the Ohio State University Comprehensive Cancer Center–The James, to learn more about the impact of certain socioeconomic factors on the completion of and clinical outcomes in patients with mantle cell lymphoma.

Transcript:

We looked at the impact of demographics and socioeconomic factors on the use of ASCT, but also on clinical outcomes—specifically overall survival. We found that after adjusting for other factors, the type of insurance and specifically having private insurance rather than Medicare, as well as receiving treatment at an academic or research facility, and certain geographical locations are actually associated with higher chances of undergoing ASCT.

In terms of clinical outcomes and survival, we found that the type of insurance was also important here. In addition, higher education and income levels were also associated with superior survival, whereas Black race was associated with inferior survival.

Reference
Sawalha Y, Radivoyevitch T, Jia X, et al. The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma. Leukemia & Lymphoma. Published online September 15, 2021. doi:10.1080/10428194.2021.1978085
Recent Videos
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.